# 2025-03061: DEA OKs Importing Trippy Ibogaine—Hallucinations for Pharma Now?

2025-03061, Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-02-26, effective Registered bulk manufacturers of the affected basic class(es), and applicants, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 28, 2025. Such persons may also file a written request for a hearing on the application on or before March 28, 2025.; PRIA reads it as touching household money (as of 2026-09-25).

- Canonical: https://policyrisk.com/federal-register/2025-03061
- As of: 2026-09-25
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-03061
- Title: Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 10731
- Published: 2025-02-26
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 28, 2025. Such persons may also file a written request for a hearing on the application on or before March 28, 2025.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-25

## In one line

DEA OKs Importing Trippy Ibogaine—Hallucinations for Pharma Now?

## Summary

Catalent Pharma Solutions, LLC wants to become an official importer of certain controlled substances, including the Schedule I drug Ibogaine. This affects companies and people involved in drug manufacturing who can comment or request a hearing by March 28, 2025. No fees or immediate changes happen now, but this is a key step in controlling drug imports.

## Abstract

Catalent Pharma Solutions, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

## Effects PRIA read

- Application to Import Schedule I Ibogaine: benefit, low. Catalent Pharma Solutions, LLC applied on November 19, 2024 to be registered as an importer of the Schedule I controlled substance ibogaine (drug code 7260). The company says it plans to import finished dosage unit products only for clinical trials, research, and analytical activities.
- Import Not Allowed for Commercial Sale: cost, low. The DEA notice says authorization will not extend to import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. The registration would only cover the specific research and clinical-trial import activities authorized under the drug code.
- Opportunity to Comment or Request Hearing: benefit, low. Registered bulk manufacturers and other applicants may submit electronic comments or objections, or file a written request for a hearing, on Catalent's application on or before March 28, 2025. Comments must be submitted through https://www.regulations.gov and hearing requests must be filed with the…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-03061 on federalregister.gov](https://www.federalregister.gov/documents/2025/02/26/2025-03061/importer-of-controlled-substances-application-catalent-pharma-solutions-llc)
- [2025-03061 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-02-26/pdf/2025-03061.pdf)

## Related
- [Previous: 2025-03060, Importer of Controlled Substances Application: Sharp Clinical Services, LLC](https://policyrisk.com/federal-register/2025-03060)
- [Next: 2025-03062, Importer of Controlled Substances Application: S&B Pharma LLC DBA Norac Pharma](https://policyrisk.com/federal-register/2025-03062)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-03061 (as of 2026-09-25).
